Roche Bets $190 Million Upfront on Hanmi's Muscle-Sparing Obesity Peptide
The $2.3 billion licensing deal for Phase 1 asset HM17321 targets a core drawback of current GLP-1 therapies: the loss of lean skeletal muscle alongside fat.
Section
Pipeline
Trials, approvals, and the drugs behind them.
Brain Shuttle Platforms Tackle the Blood-Brain Barrier for Genetic Medicines
Conjugating antisense oligonucleotides to transferrin receptor transport vehicles achieves fifty-fold deeper brain penetration, challenging the standard of invasive spinal punctures.
What Jazz’s Ziihera approval means for trastuzumab - and for PD-1 - in first-line HER2+ gastroesophageal cancer
FDA cleared two zanidatamab regimens on 25 August, including a bispecific-plus-PD-1 combination for all HER2+ advanced GEA regardless of PD-L1 status, on Phase 3 data already in NEJM.
Bristol Myers Squibb Gambles $14 Billion on Cobenfy's Non-Dopamine Mechanism
The first new pharmacological class for schizophrenia in over seventy years relies on muscarinic receptor agonism, trading dopamine motor side effects for gastrointestinal titration challenges.
What a GLP-1 antagonist means after a decade of turning the receptor on
Amylyx’s Phase 3 LUCIDITY hit on 18 August: avexitide cut Level 2/3 hypoglycemia 55% versus placebo in post-bariatric hypoglycemia , a first-in-class blocker of the same receptor the industry has spent years agonizing.
Dual-Payload ADCs Tackle Heterogeneous Resistance in Solid Tumors
Coupling topoisomerase inhibitors and microtubule disruptors onto a single antibody scaffold exerts simultaneous multi-pathway cytotoxic pressure to block emergent drug resistance.
Madrigal's Rezdiffra Clears European Hurdle in Liver Disease Battleground
The European Medicines Agency recommended approval for the first-in-class THR-beta agonist for MASH with fibrosis, setting up commercial execution against encroaching GLP-1 combinations.
Epigenetic Editing Platforms Deliver Heritable Gene Silencing Without DNA Breaks
Engineered methyltransferases achieve durable transcriptional repression across multiple cell divisions without inducing double-strand chromosomal breaks or genomic translocations.
Merck Commits $1.4 Billion to Expand Next-Generation ADC Arsenal
Aiming to diversify oncology revenues ahead of Keytruda's patent expiry, Merck licensed a topoisomerase ADC platform to develop targeted solid-tumor conjugates.
Vertex and CRISPR Push Casgevy into Pediatric Trials to Halt Early Organ Damage
Clinical investigators are expanding CRISPR gene editing into children aged five to eleven, aiming to reactivate fetal hemoglobin before cumulative sickle cell vasculopathy becomes irreversible.
Targeted Protein Degraders Overcome the 'Undruggable' Barrier with Molecular Glues
Recruiting cellular E3 ubiquitin ligases allows molecular glues and PROTACs to eliminate oncogenic transcription factors lacking classic small-molecule binding pockets.
Biotech IPO Window Reopens Selectively for Clinical-Stage De-Risked Assets
Public market investors are rewarding Phase 2 clinical proof-of-concept in metabolic disease and ADCs while preclinical platform discovery engines face strict valuation discipline.